[Genting Xinyao: no undisclosed major business progress news] June 15, in response to today's stock price closing up 54%, Genting Xinyao-B told the Financial Associated Press that the company has no undisclosed major business progress news. The company's Nefecon (Nifukang, Budesonide late release capsule) products are being approved by China NDA as planned and are expected to be approved in the fourth quarter. "Nefecon is approved in the early stages of approval. We will supply the domestic market through imports, and we have made full communication on product supply to ensure the supply of approved products. We also have the right to localize production. " Small Financial Note: Nefecon, developed by Calliditas, is the world's first targeted treatment for IgA nephropathy in 50 years for primary IgA nephropathy in adults at risk of progression to reduce proteinuria. In June 2019, Genting New Yew signed an exclusive license agreement with Calliditas for Greater China and Singapore. (financial Associated Press reporter Wang Junxian Lu Afeng)